The elevated P/E and PEG ratio of 10.21 indicate that the market is assigning a high growth premium to ELVA, likely anticipating that its proprietary separator technology will capture substantial market share in the industrial electrification space. However, this valuation appears aggressive when compared to peers like Microvast, suggesting that any failure to meet aggressive production targets at the Jamestown facility could lead to a sharp contraction in multiple expansion.

The inconsistency in ROIC reflects the heavy burden of capital expenditures required to build out domestic cell production capabilities. While the 4.0% peak in 2025Q4 shows potential for improvement, the subsequent decline suggests that the company's capital allocation strategy is currently prioritizing long-term infrastructure over immediate shareholder value creation.

The high DIO of 106 days suggests that the company is carrying substantial inventory, which may be a strategic move for the Jamestown ramp-up but also poses a risk of obsolescence or liquidity strain. Investors should monitor whether the CCC can compress as production volumes stabilize, as current levels indicate inefficient use of working capital.

While the interest coverage ratio of 2.83 provides a temporary buffer, the volatility in this metric suggests that debt service could become a constraint if revenue growth stalls or if the company requires further capital raises. The reliance on debt to fund infrastructure is a departure from historical norms and warrants close monitoring of covenant compliance.